Carregant...
Sorafenib activity and disposition in liver cancer does not depend on organic cation transporter 1 (OCT1)
Systemic therapy of advanced hepatocellular carcinoma (HCC) with the small molecule multi-kinase inhibitor sorafenib is associated with large inter-individual pharmacokinetic variability and unpredictable side effects potentially requiring dose reduction or treatment termination. Organic cation tran...
Guardat en:
| Publicat a: | Clin Pharmacol Ther |
|---|---|
| Autors principals: | , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6925656/ https://ncbi.nlm.nih.gov/pubmed/31350763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1588 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|